Lawrence A. Leiter

MDCM, FRCPC, FACP, FACE, FAHA

Investigator

Biography

Please note: Dr. Leiter is not taking any summer students.

Dr. Lawrence A. Leiter is Director of the Lipid Clinic, Associate Director of the Clinical Nutrition and Risk Factor Modification Centre and an Associate Scientist in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital in Toronto.  From 2000-2010, he was Head of the Division of Endocrinology and Metabolism. He is a Professor in the Departments of Medicine and Nutritional Sciences at the University of Toronto.

Dr. Leiter has several research interests including clinical trials on the prevention of atherosclerosis, especially in diabetes, and the dietary and pharmacologic treatment of diabetes mellitus, hyperlipidemia, hypertension, and obesity. He has over 750 publications in peer-reviewed journals. He was an investigator in many of the landmark diabetes trials including the Diabetes Control and Complications Trial (DCCT), Action to Control Cardiovascular Risk in Diabetes (ACCORD), and Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) and is on the Steering Committees of many ongoing outcome trials in both the diabetes and lipid areas. In 2018, 2019, and 2020 he was a Clarivate Analytics Top 1% Highly Cited Researcher

Dr. Leiter is a past President of the Canadian Society of Endocrinology & Metabolism (CSEM) and a past Chair of the Clinical and Scientific Section of the Canadian Diabetes Association (CDA). He has been involved in many national and international committees and consensus conferences including those of the International Diabetes Federation, CDA, Canadian Hypertension Education Program (CHEP), Canadian Cardiovascular Society (Dyslipidemia), and Obesity Canada.

For his work, he has received a number of awards including the CDA Frederick G. Banting Award and the American Diabetes Association Charles H Best Award (awarded to DCCT investigators), both for Distinguished Service. In 2016, Dr. Leiter received the Canadian Diabetes Association Long Term Achievement Award for Research and the Canadian Society of Endocrinology’s Robert Volpe Distinguished Service Award. He was also the inaugural winner of the St. Michael’s Hospital Complete Physician Award in 2009.  In 2019 was elected as a Fellow of the Canadian Academy of Health Sciences

Recent Publications

  1. Schechter, M, Melzer Cohen, C, Yanuv, I, Rozenberg, A, Chodick, G, Bodegård, J et al.. Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults. Cardiovasc Diabetol. 2022;21 (1):104. doi: 10.1186/s12933-022-01521-9. PubMed PMID:35689214 .
  2. Hramiak, I, Gerstein, HC, Leiter, LA, Yale, JF, Bajaj, HS, Stewart, J et al.. Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to iGlarLixi in the LixiLan ONE CAN randomized trial. Diabetes Obes Metab. 2022; :. doi: 10.1111/dom.14787. PubMed PMID:35670659 .
  3. Strain, WD, Frenkel, O, James, MA, Leiter, LA, Rasmussen, S, Rothwell, PM et al.. Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6. Stroke. 2022; :101161STROKEAHA121037775. doi: 10.1161/STROKEAHA.121.037775. PubMed PMID:35582947 .
  4. Furtado, RHM, Raz, I, Goodrich, EL, Murphy, SA, Bhatt, DL, Leiter, LA et al.. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Circulation. 2022;145 (21):1581-1591. doi: 10.1161/CIRCULATIONAHA.121.058103. PubMed PMID:35510542 .
  5. Steg, PG, Bhatt, DL, James, SK, Darlington, O, Hoskin, L, Simon, T et al.. Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial. Eur Heart J Cardiovasc Pharmacother. 2022; :. doi: 10.1093/ehjcvp/pvac032. PubMed PMID:35488865 .
  6. Kavanagh, ME, Chiavaroli, L, Glenn, AJ, Heijmans, G, Grant, SM, Chow, CM et al.. A Web-Based Health Application to Translate Nutrition Therapy for Cardiovascular Risk Reduction in Primary Care (PortfolioDiet.app): Quality Improvement and Usability Testing Study. JMIR Hum Factors. 2022;9 (2):e34704. doi: 10.2196/34704. PubMed PMID:35451981 PubMed Central PMC9073604.
  7. Cukierman-Yaffe, T, Gerstein, HC, Basile, J, Bethel, MA, Cardona-Muñoz, EG, Conget, I et al.. Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial. J Clin Endocrinol Metab. 2022; :. doi: 10.1210/clinem/dgac200. PubMed PMID:35446415 .
  8. Klonoff, DC, Wang, J, Rodbard, D, Kohn, MA, Li, C, Liepmann, D et al.. A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. J Diabetes Sci Technol. 2022; :19322968221085273. doi: 10.1177/19322968221085273. PubMed PMID:35348391 .
  9. Laufs, U, Ballantyne, CM, Banach, M, Bays, H, Catapano, AL, Duell, PB et al.. Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. J Clin Lipidol. ;16 (3):286-297. doi: 10.1016/j.jacl.2022.03.001. PubMed PMID:35346603 .
  10. Verma, S, Al-Omran, M, Leiter, LA, Mazer, CD, Rasmussen, S, Saevereid, HA et al.. Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease. Diabetes Obes Metab. 2022;24 (7):1288-1299. doi: 10.1111/dom.14700. PubMed PMID:35332654 .
Search PubMed

Affiliations & Other Activities

  • Director, Lipid Clinic, St. Michael’s Hospital
  • Associate Director, Clinical Nutrition and Risk Factor Modification Centre, St. Michael’s Hospital
  • Professor, Departments of Medicine and Nutritional Sciences, University of Toronto